Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review

Simple Summary This review aims to better define the clinical, pathological, and molecular features of the novel lymphoproliferative disease termed indolent T-cell lymphoproliferative disorder of the gastro-intestinal tract (iTLPD-GI), to discuss potential pitfalls in differentiating this entity from other neoplastic and non-neoplastic disorders arising at the same site, and to point out a biomarker-based approach to the diagnosis. iTLPD-GI is a low-grade clonal T-cell lymphoproliferative disease arising in GI organs. It is an uncommon disease, and only recently has it been enlisted as a distinct provisional entity in the current WHO Classification. Data from the literature disclose high heterogeneity in terms of pathological and molecular features; on the other hand, establishing an accurate diagnosis of iTLPD-GI is of pivotal importance, since treatment options are different from that of other, more frequent lymphomas that arise in the gastrointestinal tract. In this review, we aimed to better define this novel entity, and to identify useful diagnostic biomarkers; moreover, we provide a biomarker-based approach to the diagnosis and describe the most common issues in differentiating iTLPD-GI from other neoplastic and non-neoplastic disorders.

Automated summary

This review aims to define the clinical, pathological, and molecular features of iTLPD-GI, discuss potential pitfalls in differentiating this disease from others, and provide a biomarker-based approach to diagnosis. High heterogeneity in pathological and molecular features of iTLPD-GI is noted, highlighting the importance of accurately diagnosing this rare disease for appropriate treatment.